Company intelligence / Profile preview

SK Life Science, Inc.

Ownership: Private
Employees: ~282
Development stage: Commercial

Overview

SK Life Science has successfully commercialized cenobamate for epilepsy in the U.S. and has a robust pipeline of eight compounds targeting CNS disorders and oncology. Clinical-stage assets span from Phase 1 through Phase 3 trials across multiple indications including epilepsy subtypes and psychiatric/neurodevelopmental disorders. The company leverages both traditional small molecule approaches as well as next-generation targeted protein degradation technologies via its labs subsidiary.

Therapeutic areas: OncologyPsychiatryNeurology
Modalities: Small moleculesTargeted protein degraders
Industry: Biotech

Drug pipeline

5 assets

carisbamate

4 more assets in the full pipeline.

Partnerships

Clinical development partnerships noted for some assets but no major disclosed pharma co-development deals found.

Beyond the preview

Go deeper on SK Life Science, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK Life Science, Inc..